LifeScience WorldWide’s Post

🌟 Opportunity Alert for Sickle Cell Researchers! 🌟 Be part of a groundbreaking moment and have your work published in the inaugural issues of the Journal of Sickle Cell Disease, now proudly partnered with Oxford University Press. This is your chance to contribute to the world's understanding of sickle cell disease with your late-breaking research associated with our Symposium. All accepted submissions will be featured as a supplement in the Journal, providing a prestigious platform for your findings. Plus, with indexing for MEDLINE, your work will be accessible and citable by the global research community. 🔔 Final Call for Submissions: Don't miss the April 1 deadline for late-breaking abstracts. Our partnership with Oxford University Press underscores the importance of this deadline to ensure your research makes its mark. Seize this unique opportunity to elevate sickle cell research and make a lasting impact. #SickleCellResearch #CallForAbstracts #OxfordUniversityPress #JournalOfSickleCellDisease #LateBreaking #MEDLINEIndexed #MakeAnImpact #ResearchOpportunity #SickleCellAwareness #ResearchImpact #ScientificPublishing #GlobalHealth #SickleCellAdvocacy

My latest article on targeting bioelectrical pathways for aging and regeneration is out. If you don't know him yet, I suggest you take a look at Michael Levin's research in this space. An absolute legend! https://lnkd.in/dVxybwJJ

We are starting the new year with some exciting strides in genetic research! A team of scientists from the Icahn School of Medicine at Mount Sinai has unveiled a groundbreaking statistical technique, #BridgePRS, to boost disease prediction accuracy in non-European populations, especially those of African descent. Key Highlights of this research include: 1. Enhanced Disease Prediction: The innovative "BridgePRS" addresses the limitations of current polygenic risk scores (PRS), predominantly tailored to individuals of European ancestry. 2. Reduced Health Care Inequities: By leveraging shared genetic effects across ancestries, this development promises more accurate disease prediction for diverse ethnic groups, fostering a future of personalized and precise medical interventions. This breakthrough is a significant step towards reducing healthcare disparities and advancing personalized medicine for all. Kudos to the talented team at Icahn School of Medicine at Mount Sinai for this impactful contribution to #genomics Read more about their pioneering work here: https://lnkd.in/dUVVFxd5 #genomics #healthcareequity #precisionmedicine #myafrodna #dnaresearch #researchinnovation

We are excited to share our latest publication, "Newborn screening in Mexico and Latin America: present and future." This paper reviews the progress made in implementing and expanding newborn screening (NBS) programs across Latin America, with a special focus on Mexico. Read the publication here: https://lnkd.in/d6STaQdH Despite significant advancements over the past 50 years, many children in the region still do not fully benefit from this vital public health strategy. The study also explores the potential future of NBS in light of new technologies like genomic sequencing, considering the economic and technological constraints in the region. Dive into our findings and join the conversation on how we can improve NBS for all children in Latin America.

A must watch for anyone interested in #ParkinsonsClinicalResearch Listen to Dr Simon Stott, hosted by No Silver Bullet 4 PD presenting key #Parkinsons research takeaways from 2023 & highlighting promising research developments to look out for in 2024. https://lnkd.in/efMfnq8d Key topics covered are: - Studies testing antibody treatments targeting Alpha synuclein aggregation; can slowing the spread of aggregated alpha synuclein help to slow the progression of Parkinson's? - Studies exploring whether GLP1 receptor agonists (drugs usually used to treat diabetes) can slow the progression of Parkinson's. - Promising experimental surgical procedures, including cell transplantation therapies, currently being tested to assess their ability to slow the progression of Parkinson's. - How the progression of Parkinson's can be monitored through technologies, including data collection from wearables and sensor based equipment. - Other interesting topics covered include research relating to GDNF genetic therapy approach; adaptive Deep Brain Stimulation (individualised stimulation in response to real time brain activity); and lifestyle interventions such as prebiotics. Finally, 2024 will be a big year for the exciting EJS ACT-PD initiative, learn more here: https://ejsactpd.com/ The momentum of Parkinson's clinical research is growing and 2024 hopes to be a prosperous year for exciting results and future directions for studies aiming to slow the progression of Parkinson's. Be sure to follow both Dr Simon Stott @ScienceofPD and No Silver Bullet @NSB4PD on X (Twitter) Cure Parkinson's

In the latest blog Yvonne Couch, we are invited to examine the significance of aging within pre-clinical research using mice models. Yvonne articulates the necessity for this paradigm shift, underscoring the translational benefits it could bring in understanding age-related human diseases. She raises critical points about the current research landscape and how it could evolve to better serve an aging global population (and how funders need to keep up). It’s an essential read for professionals in the biomedical field to engage in this emerging dialogue. https://lnkd.in/e6vEHAWs

"Genetic factors may contribute to disparities in Alzheimer’s risk in African Americans, a historically underrepresented group in Alzheimer’s genetics research. The study findings highlight the importance of including diverse populations in genetic data to better understand genetic determinants of Alzheimer’s. Further research on these genetic factors may lead to potential new biomarkers for Alzheimer’s genetic risk assessment in individuals of African ancestry." #dementia #dementiaawareness #alzheimers #alzheimersawareness #endalz #endalznow #endalzheimers Family-based study identifies potential new genetic factors linked to Alzheimer’s risk in people with African ancestry | National Institute on Aging (nih.gov)

Today a woman in her 30s faces higher odds of a cancer diagnosis than her grandmother did at her age two generations ago. Cancer incidence and mortality are rising in millennials and even younger populations, according to American Cancer Society (ACS) data, while rates among older Americans are declining. In July, a study found that both members of Generation X and Millennials face a higher risk than older generations of 17 types of cancer. #health #medical #sustainability

It was a real honour to chair and speak at the morning session of the Westminster health forum. As genomics becomes a more accessible word for clinical application, the reality on the ground and the aspirations of research have to come together for a real world clinical pathway role at a population level. As I said we have made a Good start, but we need more to go on and we still need to address the elephant in the room which I am afraid remains how to have a wider diversity of genomes and have a truly equitable genomics service. Being a bit more adventurous on having multiple local hubs for sequencing should also be considered as the cost and capital spend for sequencing has dropped sufficiently and so to improve diagnostic time and to engage with communities where the service has to step up this would help especially whereby local university sequencing in most areas has the dual capability and with sufficient training and bioinformatic support this would lead to a more effective streamlined use of genomics in clinical pathways. Training of clinicians and the need for more bioinformatic support was discussed and how for precision medicine the need for centre hubs like ours is a must. Also Trust in the process of genomic diagnosis is going to be important and sometimes the optics of policies and leadership teams needs to be thought of if we want to engage with all communities and the public (just ask any politician !) . Non legacy helicopter large scale projects do little to promulgate confidence in many diverse communities already realing from the effects of covid which highlighted health inequalities in the most starkest of fashions. #genomics #populationhealth #precisionmedicine #clinicalpathways #pangenomes #diagnositcs

https://lnkd.in/g3hsCzMG = part of the approach on the purpose of GLOBAL HEALTH SCIENCE INSTITUTE. FYI: It's okay if you don't agree, as like in any area of life bad habits are also hard to give up in biomedical research. However, we look for those who think of novel opportunities as too many things are not working from the patient's point of view. Such as where Stage 3 and 4 #cancers are stuck in the 1930s…and so is #ALS.    “When we catch cancer early, we knock it out three-fourths of the time. But despite having spent $250 billion on cures, state three and four patients’ chances of survival are not better today that in 1930.” Cancer & Evolution Symposium. + “Today, ALS is diagnosed at the equivalent state of Stage 4 cancer, while our treatment measurements remain archaic.” I. Navar, Founder & CEO of EverythingALS Imagine wanting to get a second medical opinion and you are given the clinic's partner or someone who went to the same Residency/Medical School. That's not a second opinion, that's a confirmation of the first opinion...not the same thing. We are not the same thing, but if you want to help us out in some way with one of our projects, explore our website and then contact us.